{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:36Z","timestamp":1790916996034,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01246-9","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:55:27Z","timestamp":1787043327000},"page":"669-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8927","authenticated-orcid":false,"given":"Ken","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abood","family":"Okal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"1","key":"1246_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112\u201322. https:\/\/doi.org\/10.1002\/cpt.1674.","journal-title":"Clin Pharmacol Ther"},{"issue":"26","key":"1246_CR2","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323. https:\/\/doi.org\/10.1182\/blood-2014-12-580068.","journal-title":"Blood"},{"issue":"6","key":"1246_CR3","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361. https:\/\/doi.org\/10.1016\/S2352-3026(21)00057-0.","journal-title":"Lancet Haematol."},{"key":"1246_CR4","unstructured":"U. S. Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed 8 Apr 2026."},{"issue":"10254","key":"1246_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"1","key":"1246_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.2561","volume":"112","author":"K Ogasawara","year":"2022","unstructured":"Ogasawara K, Lymp J, Mack T, Dell\u2019Aringa J, Huang CP, Smith J, et al. In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma. Clin Pharmacol Ther. 2022;112(1):81\u20139. https:\/\/doi.org\/10.1002\/cpt.2561.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1246_CR7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jcyt.2022.03.013","volume":"24","author":"J Teoh","year":"2022","unstructured":"Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19(+) hematologic indications. Cytotherapy. 2022;24(9):962\u201373. https:\/\/doi.org\/10.1016\/j.jcyt.2022.03.013.","journal-title":"Cytotherapy"},{"issue":"14","key":"1246_CR8","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384. https:\/\/doi.org\/10.1182\/blood.2022018730.","journal-title":"Blood"},{"issue":"8","key":"1246_CR9","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30(8):2199\u2013207. https:\/\/doi.org\/10.1038\/s41591-024-02986-9.","journal-title":"Nat Med"},{"issue":"10532","key":"1246_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(25)02435-3","volume":"407","author":"ML Palomba","year":"2026","unstructured":"Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, et al. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026;407(10532):963\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(25)02435-3.","journal-title":"Lancet"},{"issue":"8","key":"1246_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00339-4.","journal-title":"Lancet Oncol"},{"issue":"10402","key":"1246_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;402(10402):641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(23)01052-8.","journal-title":"Lancet"},{"issue":"10","key":"1246_CR13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42(10):1146\u201357. https:\/\/doi.org\/10.1200\/JCO.23.02214.","journal-title":"J Clin Oncol"},{"issue":"10343","key":"1246_CR14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308. https:\/\/doi.org\/10.1016\/S0140-6736(22)00662-6.","journal-title":"Lancet"},{"issue":"12","key":"1246_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","volume":"60","author":"K Ogasawara","year":"2021","unstructured":"Ogasawara K, Dodds M, Mack T, Lymp J, Dell\u2019Aringa J, Smith J. Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma. Clin Pharmacokinet. 2021;60(12):1621\u201333. https:\/\/doi.org\/10.1007\/s40262-021-01039-5.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1246_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/cpt.3111","volume":"115","author":"J Gokemeijer","year":"2024","unstructured":"Gokemeijer J, Balasubramanian N, Ogasawara K, Grudzinska-Goebel J, Upreti VV, Mody H, et al. An IQ consortium perspective on best practices for bioanalytical and immunogenicity assessment aspects of CAR-T and TCR-T cellular therapies development. Clin Pharmacol Ther. 2024;115(2):188\u2013200. https:\/\/doi.org\/10.1002\/cpt.3111.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1246_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/cpt.2986","volume":"114","author":"H Mody","year":"2023","unstructured":"Mody H, Ogasawara K, Zhu X, Miles D, Shastri PN, Gokemeijer J, et al. Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective. Clin Pharmacol Ther. 2023;114(3):530\u201357. https:\/\/doi.org\/10.1002\/cpt.2986.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1246_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2026.100049","volume":"2","author":"CF Jacobs","year":"2026","unstructured":"Jacobs CF, Simon-Molas H, Cretenet G, Gutschow M, Collett G, Colonna L, et al. Lisocabtagene maraleucel outcome in large B-cell lymphoma associates with memory composition and mitochondrial fitness of T cells. Blood Immunol Cell Ther. 2026;2(2):100049. https:\/\/doi.org\/10.1016\/j.bict.2026.100049.","journal-title":"Blood Immunol Cell Ther"},{"issue":"9","key":"1246_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103925","volume":"114","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Hu H, Ogasawara K, Li Y. Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a Student\u2019s t-based M3 censoring approach for robust handling of outliers and BLQ data. J Pharm Sci. 2025;114(9):103925. https:\/\/doi.org\/10.1016\/j.xphs.2025.103925.","journal-title":"J Pharm Sci"},{"issue":"5","key":"1246_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","volume":"24","author":"A Mulvey","year":"2025","unstructured":"Mulvey A, Trueb L, Coukos G, Arber C. Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discov. 2025;24(5):379\u201397. https:\/\/doi.org\/10.1038\/s41573-024-01100-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1246_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137(3):323\u201335. https:\/\/doi.org\/10.1182\/blood.2020006770.","journal-title":"Blood"},{"key":"1246_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004483","author":"EM Holland","year":"2022","unstructured":"Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004483.","journal-title":"J Immunother Cancer"},{"issue":"15 Suppl","key":"1246_CR23","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2020.38.15_suppl.8012","volume":"38","author":"FL Locke","year":"2020","unstructured":"Locke FL, Bartlett NL, Jacobson CA, Oluwole OO, Munoz J, Lekakis LJ, et al. Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1. J Clin Oncol. 2020;38(15 Suppl):8012. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8012.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1246_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41409-023-02041-0","volume":"58","author":"JN Brudno","year":"2023","unstructured":"Brudno JN, Kochenderfer JN. Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR. Bone Marrow Transplant. 2023;58(10):1157\u20139. https:\/\/doi.org\/10.1038\/s41409-023-02041-0.","journal-title":"Bone Marrow Transplant"},{"key":"1246_CR25","unstructured":"ClinicalTrials.gov. Nonconforming lisocabtagene maraleucel expanded access protocol. 2025. https:\/\/clinicaltrials.gov\/study\/NCT04400591. Accessed 7 Apr 2026."},{"issue":"5","key":"1246_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404\u201316. https:\/\/doi.org\/10.1182\/blood.2023020854.","journal-title":"Blood"},{"key":"1246_CR27","unstructured":"U.S. Food and Drug Administration. Long term follow-up after administration of human gene therapy products\u2013guidance for industry. 2020."},{"key":"1246_CR28","unstructured":"Lunning M, Anderson Jr. LD, Berdeja J, Munshi N, Rajeski K, Westin J, et al. Long-term safety of CAR T cell therapy with lisocabtagene maraleucel and idecabtagene vicleucel: analysis of second primary malignancy and vector-associated outcomes. HemaSphere. 2026;4233-4234"},{"key":"1246_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-03051","author":"L Stepan","year":"2026","unstructured":"Stepan L, Ansari S, Abramson JS, Okal A, Dell\u2019Aringa J, Thompson EG, et al. Circulating tumor DNA assessment of disease response in large B-cell lymphoma: lisocabtagene maraleucel versus autologous stem cell transplantation standard therapy. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO-25-03051.","journal-title":"J Clin Oncol"},{"key":"1246_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12254-025-01069-w","volume":"18","author":"N Rotter","year":"2025","unstructured":"Rotter N. Late toxicities and surveillance strategies after anti-CD19 and anti-BCMA CAR-T cell therapy. Memo Mag Eur Med Oncol. 2025;18:328\u201332. https:\/\/doi.org\/10.1007\/s12254-025-01069-w.","journal-title":"Memo Mag Eur Med Oncol."},{"issue":"3","key":"1246_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","volume":"106","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106(3):795\u2013802. https:\/\/doi.org\/10.1182\/blood-2004-08-3198.","journal-title":"Blood"},{"issue":"6","key":"1246_CR32","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood"},{"issue":"24","key":"1246_CR33","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.1182\/bloodadvances.2024014641","volume":"8","author":"I Sahai","year":"2024","unstructured":"Sahai I, Borgman P, Yates B, Rosenzweig S, Rampertaap S, Rankin AW, et al. Incidence of preexisting B-cell aplasia in B-ALL: implications for post-CAR T-cell monitoring. Blood Adv. 2024;8(24):6329\u201333. https:\/\/doi.org\/10.1182\/bloodadvances.2024014641.","journal-title":"Blood Adv"},{"issue":"10","key":"1246_CR34","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5(10):e362. https:\/\/doi.org\/10.1038\/bcj.2015.86.","journal-title":"Blood Cancer J"},{"key":"1246_CR35","unstructured":"Bristol Myers Squibb. BREYANZI: summary of product characteristics. 2025."},{"key":"1246_CR36","unstructured":"Bristol Myers Squibb. BREYANZI: US prescribing information. 2026."},{"key":"1246_CR37","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1002\/cpt.3120","volume":"115","author":"Y Chen","year":"2024","unstructured":"Chen Y, Balasubramanian N, Cummings J, Lin H, Ou SS, Tuazon S, et al. Exposure response (E\u2013R) relationships of lisocabtagene maraleucel (liso-cel) monotherapy in patients with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Clin Pharmacol Ther. 2024;115:S87.","journal-title":"Clin Pharmacol Ther"},{"key":"1246_CR38","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/cpt.3065","volume":"115","author":"R Nishii","year":"2024","unstructured":"Nishii R, Lin H, Chen W, Balasubramanian N, Cummings J, Farazi T, et al. Cellular kinetics of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, lisocabtagene maraleucel (liso-cel) and its association with efficacy and safety in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL). Clin Pharmacol Ther. 2024;115:S52.","journal-title":"Clin Pharmacol Ther"},{"key":"1246_CR39","unstructured":"U.S. Food and Drug Administration. Clinical review and evaluation Memo\u2014BREYANZI. 2025."},{"key":"1246_CR40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032270","author":"JS Abramson","year":"2026","unstructured":"Abramson JS, Siddiqi T, Gordon LI, Lunning MA, Wang M, Arnason JE, et al. Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R\/R LBCL. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032270.","journal-title":"Blood"},{"issue":"24","key":"1246_CR41","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO-25-00399","volume":"43","author":"M Kamdar","year":"2025","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study. J Clin Oncol. 2025;43(24):2671\u20138. https:\/\/doi.org\/10.1200\/JCO-25-00399.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1246_CR42","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/bloodadvances.2024015262","volume":"9","author":"A Sehgal","year":"2025","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel for R\/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025;9(15):3694\u2013705. https:\/\/doi.org\/10.1182\/bloodadvances.2024015262.","journal-title":"Blood Adv"},{"key":"1246_CR43","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1182\/blood-2024-200840","volume":"144","author":"T Siddiqi","year":"2024","unstructured":"Siddiqi T, Gauthier J, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): updated follow-up of Transcend CLL 004. Blood. 2024;144:4633. https:\/\/doi.org\/10.1182\/blood-2024-200840.","journal-title":"Blood"},{"key":"1246_CR44","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2024-198509","volume":"144","author":"LJ Nastoupil","year":"2024","unstructured":"Nastoupil LJ, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): transcend FL 2-year follow-up. Blood. 2024;144:4387. https:\/\/doi.org\/10.1182\/blood-2024-198509.","journal-title":"Blood"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01246-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:50Z","timestamp":1790916710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01246-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01246-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by Bristol Myers Squibb.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.O., R.N., Y.C., N.B., and A.O. are employees of Bristol Myers Squibb and hold stock in Bristol Myers Squibb.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new data were generated or analyzed in this review. Data sharing is not applicable to this article.","order":3,"name":"Ethics","label":"Data sharing and data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.O. conceived the article. K.O. performed the literature review and drafted the manuscript. All authors contributed to interpretation of the literature, critically revised the manuscript for important intellectual content, and approved the final version. All authors are responsible for the content and conclusions of the manuscript.","order":4,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}